1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
|
<html xmlns:v="urn:schemas-microsoft-com:vml"
xmlns:o="urn:schemas-microsoft-com:office:office"
xmlns:w="urn:schemas-microsoft-com:office:word"
xmlns:st1="urn:schemas-microsoft-com:office:smarttags"
xmlns="http://www.w3.org/TR/REC-html40">
<head>
<meta http-equiv=Content-Type content="text/html; charset=iso-8859-1">
<meta name=ProgId content=Word.Document>
<meta name=Generator content="Microsoft Word 11">
<meta name=Originator content="Microsoft Word 11">
<link rel=File-List href="cameron_files/filelist.xml">
<link rel=Edit-Time-Data href="cameron_files/editdata.mso">
<!--[if !mso]>
<style>
v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style>
<![endif]-->
<title>DoctorYourself.com - Cameron Protocol</title>
<o:SmartTagType namespaceuri="urn:schemas-microsoft-com:office:smarttags"
name="place"/>
<o:SmartTagType namespaceuri="urn:schemas-microsoft-com:office:smarttags"
name="country-region"/>
<o:SmartTagType namespaceuri="urn:schemas-microsoft-com:office:smarttags"
name="PostalCode"/>
<o:SmartTagType namespaceuri="urn:schemas-microsoft-com:office:smarttags"
name="City"/>
<o:SmartTagType namespaceuri="urn:schemas-microsoft-com:office:smarttags"
name="PlaceType"/>
<o:SmartTagType namespaceuri="urn:schemas-microsoft-com:office:smarttags"
name="PlaceName"/>
<!--[if gte mso 9]><xml>
<o:DocumentProperties>
<o:Author> </o:Author>
<o:Template>Normal</o:Template>
<o:LastAuthor> </o:LastAuthor>
<o:Revision>3</o:Revision>
<o:TotalTime>9</o:TotalTime>
<o:Created>2007-12-20T20:53:00Z</o:Created>
<o:LastSaved>2007-12-21T13:00:00Z</o:LastSaved>
<o:Pages>1</o:Pages>
<o:Words>2804</o:Words>
<o:Characters>15988</o:Characters>
<o:Company> </o:Company>
<o:Lines>133</o:Lines>
<o:Paragraphs>37</o:Paragraphs>
<o:CharactersWithSpaces>18755</o:CharactersWithSpaces>
<o:Version>11.5606</o:Version>
</o:DocumentProperties>
</xml><![endif]--><!--[if gte mso 9]><xml>
<w:WordDocument>
<w:ValidateAgainstSchemas/>
<w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>
<w:IgnoreMixedContent>false</w:IgnoreMixedContent>
<w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>
<w:BrowserLevel>MicrosoftInternetExplorer4</w:BrowserLevel>
</w:WordDocument>
</xml><![endif]--><!--[if gte mso 9]><xml>
<w:LatentStyles DefLockedState="false" LatentStyleCount="156">
</w:LatentStyles>
</xml><![endif]--><!--[if !mso]><object
classid="clsid:38481807-CA0E-42D2-BF39-B33AF135CC4D" id=ieooui></object>
<style>
st1\:*{behavior:url(#ieooui) }
</style>
<![endif]-->
<style>
<!--
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{mso-style-parent:"";
margin:0in;
margin-bottom:.0001pt;
mso-pagination:widow-orphan;
font-size:12.0pt;
font-family:"Times New Roman";
mso-fareast-font-family:"Times New Roman";}
a:link, span.MsoHyperlink
{color:blue;
text-decoration:underline;
text-underline:single;}
a:visited, span.MsoHyperlinkFollowed
{color:blue;
text-decoration:underline;
text-underline:single;}
p
{mso-margin-top-alt:auto;
margin-right:0in;
mso-margin-bottom-alt:auto;
margin-left:0in;
mso-pagination:widow-orphan;
font-size:12.0pt;
font-family:"Times New Roman";
mso-fareast-font-family:"Times New Roman";}
span.grame
{mso-style-name:grame;}
@page Section1
{size:8.5in 11.0in;
margin:1.0in 1.25in 1.0in 1.25in;
mso-header-margin:.5in;
mso-footer-margin:.5in;
mso-paper-source:0;}
div.Section1
{page:Section1;}
-->
</style>
<!--[if gte mso 10]>
<style>
/* Style Definitions */
table.MsoNormalTable
{mso-style-name:"Table Normal";
mso-tstyle-rowband-size:0;
mso-tstyle-colband-size:0;
mso-style-noshow:yes;
mso-style-parent:"";
mso-padding-alt:0in 5.4pt 0in 5.4pt;
mso-para-margin:0in;
mso-para-margin-bottom:.0001pt;
mso-pagination:widow-orphan;
font-size:10.0pt;
font-family:"Times New Roman";
mso-ansi-language:#0400;
mso-fareast-language:#0400;
mso-bidi-language:#0400;}
</style>
<![endif]-->
<meta name=Author content="Andrew W. Saul, Ewan Cameron, M.D.">
<meta name=KeyWords
content="Ewan Cameron, Linus Pauling, vitamin C, chemotherapy, Vale of Leven Hospital, Scotland, cancer, metastases, tumor, carcinoma">
<!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="3074"/>
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1"/>
</o:shapelayout></xml><![endif]-->
<!-- ADD style1 ===================== -->
<style type="text/css">
#TFlag
{
float:right;
font-size:105%;
line-height:105%;
padding:.15 em;
margin:.15 em;
}
img.top
{
vertical-align:text-top;
}
</style>
<!-- END ADD style1 ===================== -->
</head>
<body bgcolor=white background="../../../../../images/architek0H.gif"
lang=EN-US link=blue vlink=blue style='tab-interval:.5in'>
<!-- ADD TFlag ===================== -->
<span id ="TFlag">
<a href="#translator_block">
Click here to translate this page.
<img class="top" SRC="images/TranslateFlag.jpg" alt="translate gadget at page bottom" height=36>
</a>
</span>
<!-- END ADD TFlag ===================== -->
<div class=Section1>
<p class=MsoNormal> </p>
<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
style='mso-cellspacing:0in;mso-padding-alt:0in 0in 0in 0in'>
<tr style='mso-yfti-irow:0;mso-yfti-firstrow:yes;mso-yfti-lastrow:yes'>
<td width=132 style='width:99.0pt;padding:0in 0in 0in 0in'>
<p class=MsoNormal><img width=117 height=105 id="_x0000_i1025"
src="images/logo1.GIF"></p>
</td>
<td width=16 style='width:12.0pt;padding:0in 0in 0in 0in'>
<p class=MsoNormal><o:p> </o:p></p>
</td>
<td style='padding:0in 0in 0in 0in'>
<p class=MsoNormal><img width=365 height=60 id="_x0000_i1026"
src="images/dystitle2.JPG"><br>
<img width=365 height=20 id="_x0000_i1027"
src="images/dysaut.JPG"></p>
</td>
<td style='padding:0in 0in 0in 0in'>
<p class=MsoNormal><b><span style='font-family:Arial'>The Dr. Ewan Cameron
Vitamin C Treatment Protocol for Cancer</span></b></p>
</td>
</tr>
</table>
<div class=MsoNormal align=center style='text-align:center'>
<hr size=2 width="100%" align=center>
</div>
<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
style='mso-cellspacing:0in;mso-padding-alt:0in 0in 0in 0in'>
<tr style='mso-yfti-irow:0;mso-yfti-firstrow:yes'>
<td width=132 valign=top style='width:99.0pt;padding:0in 0in 0in 0in'>
<p class=MsoNormal><span style='color:red'>Cameron Protocol</span> <br>
<a href="index.html">Home</a></p>
</td>
<td width=18 style='width:13.5pt;padding:0in 0in 0in 0in'>
<p class=MsoNormal><o:p> </o:p></p>
</td>
<td valign=top style='padding:0in 0in 0in 0in'>
<p class=MsoNormal><i><span style='font-family:Arial'>"It has been known
for many years that cancer patients have depressed circulating, cellular, and
tissue ascorbate reserves, and ascorbate (vitamin C) is involved in many
aspects of host resistance to cancer." </span></i> </p>
<p><b style='mso-bidi-font-weight:normal'><span style='font-family:Arial'>PROTOCOL
FOR THE USE OF INTRAVENOUS VITAMIN C IN THE TREATMENT OF CANCER (1986)</span>
<o:p></o:p></b></p>
<p><span style='font-size:11.0pt;font-family:Arial'>by Ewan Cameron, MD,
FRCS, Medical Director, Linus Pauling Institute of Science and Medicine.
Formerly Chief of Surgery, Vale of <st1:PlaceName w:st="on">Leven</st1:PlaceName>
<st1:PlaceType w:st="on">Hospital</st1:PlaceType>, <st1:place w:st="on"><st1:City
w:st="on">Lochlomondside</st1:City>, <st1:PostalCode w:st="on">G83 OUA</st1:PostalCode>,
<st1:country-region w:st="on">Scotland</st1:country-region></st1:place></span><span
style='font-size:11.0pt'> <o:p></o:p></span></p>
<p><span style='font-size:11.0pt;font-family:Arial'>Reprinted with permission
of the Linus Pauling Institute, <st1:place w:st="on"><st1:PlaceName w:st="on">Oregon</st1:PlaceName>
<st1:PlaceType w:st="on">State</st1:PlaceType> <st1:PlaceType w:st="on">University</st1:PlaceType></st1:place></span><span
style='font-size:11.0pt'> <o:p></o:p></span></p>
<p><span style='font-size:11.0pt;font-family:Arial'>(Note: Within this paper,
Dr. Cameron cited 38 references, and recommended 11 additional sources. The
complete bibliography is posted at <span style='mso-bidi-font-weight:bold'><a
href="http://www.doctoryourself.com/biblio_cameron.html">http://www.doctoryourself.com/biblio_cameron.html</a></span></span><span
style='font-size:11.0pt'> ) <o:p></o:p></span></p>
<p><i><span style='font-size:11.0pt;font-family:Arial'>Important Note: This
paper is designed specifically for, and addressed specifically to, licensed
medical physicians.</span></i><span style='font-size:11.0pt'> <br>
<o:p></o:p></span></p>
<p><b><span style='font-size:11.0pt;font-family:Arial'>MEDICO-LEGAL
PRECAUTIONS</span></b><span style='font-size:11.0pt'> <o:p></o:p></span></p>
<p><span style='font-size:11.0pt;font-family:Arial'>More than one thousand
(as of 1986) cancer patients have been treated by supplemental ascorbate
(vitamin C) in a few canters in <st1:country-region w:st="on">Scotland</st1:country-region>
and <st1:place w:st="on"><st1:country-region w:st="on">Japan</st1:country-region></st1:place>.
In addition, it has been reliably estimated that at least 100,000 cancer
patients in the <st1:place w:st="on"><st1:country-region w:st="on">United
States</st1:country-region></st1:place> are currently ingesting ascorbates
with or without the tacit consent and knowledge of their physicians.
Nevertheless this form of treatment must still be considered experimental and
unproven. Before initiating treatment, the physician must obtain signed
informed consent stressing this point. The administration of ascorbate either
orally or intravenously is not illegal anywhere in the <st1:country-region
w:st="on">United States</st1:country-region> or <st1:place w:st="on"><st1:country-region
w:st="on">Canada</st1:country-region></st1:place>.</span><span
style='font-size:11.0pt'> <br>
<o:p></o:p></span></p>
<p><b><span style='font-size:11.0pt;font-family:Arial'>TREATMENT RATIONALE</span></b><span
style='font-size:11.0pt'> <o:p></o:p></span></p>
<p><span style='font-size:11.0pt;font-family:Arial'>The reasons for the
expectation that supplemental ascorbate should be of some benefit to all
cancer patients have been given in detail elsewhere. To summarize, it has
been known for many years that cancer patients have depressed circulating,
cellular, and tissue ascorbate reserves, and ascorbate (vitamin C) is
involved in many aspects of host resistance to cancer. Moreover, <b>ascorbate
administered in pharmacological doses enhances many parameters of the immune
response to levels far above the somewhat arbitrary "normal" range,
including cell-mediated immunity and the endogenous production of interferon.
There is also some laboratory evidence behind the strong clinical impression
that in certain situations attainable concentrations of ascorbate may have a
selective cytotoxic effect on malignant cells while being harmless to normal
cells</b>, resulting in cancer regression in rare instances.</span><span
style='font-size:11.0pt'> <br>
<o:p></o:p></span></p>
<p><b><span style='font-size:11.0pt;font-family:Arial'>THE CONTROVERSY</span></b><span
style='font-size:11.0pt'> <o:p></o:p></span></p>
<p><span style='font-size:11.0pt;font-family:Arial'>Despite the above, it is
understandably difficult to believe that a simple cheap and safe substance
such as vitamin C could have any possible value against such a bafflingly
complex disease as cancer. Such reasonable skepticism was seemingly confirmed
by the publication of <b>two negative trials carried out by respected
investigators at the Mayo Clinic. However, careful reading of these two
papers shows that these much publicized results were far from conclusive.
Both trials relied upon oral medication only</b>, and in the form of 20
ascorbate capsules to be swallowed per day, compared to controls swallowing
20 capsules of an easily recognized placebo. In the first trial 127
far-advanced patients suffering from miscellaneous cancers were studied,
almost all of whom had already been unsuccessfully treated by chemotherapy or
radiation therapy and often both. Such immune-compromised patients would be
the least likely to derive any benefit from vitamin C. Furthermore no checks
were carried out to ensure that controls were not self-medicating with this
freely available substance. </span><span style='font-size:11.0pt'> <o:p></o:p></span></p>
<p><span style='font-size:11.0pt;font-family:Arial'>The second trial was even
more inconclusive. Ascorbate or placebo was administered to 100 patients with
inoperable colon cancer, abruptly discontinued when tumor progression was
detected at a median time of 10 weeks, then replaced in the majority by
chemotherapy. From the published data <b>in the second paper it is clear that
the few controls tested were also self-medicating with vitamin C</b>. Thus
the ascorbate treatment of cancers remains unproven and experimental, but by
no means disproved.</span><span style='font-size:11.0pt'> <br>
<o:p></o:p></span></p>
<p><b><span style='font-size:11.0pt;font-family:Arial'>TREATMENT CHOICE</span></b><span
style='font-size:11.0pt'> <o:p></o:p></span></p>
<p><span style='font-size:11.0pt;font-family:Arial'>Cancer treatment must
never be regarded as an alternative to proven conventional methods of cancer treatment,
but instead as a supportive measure employed alongside whatever standard
method is indicated. There is some evidence of synergism. Thus ascorbate has
long been known to promote healing, and should accelerate convalescence from
major cancer surgery. Ascorbic acid and its metabolite dehydroascorbic acid
radiosensitize hypoxic tumor cells with the potential to enhance the
therapeutic effects of radiation. Ascorbate enhances the chemotherapeutic
activity of some chemotherapeutic drugs, including adriamycin, while there is
considerable anecdotal evidence that ascorbate diminishes to a certain extent
the unpleasant side-effects of cytotoxic chemotherapy without apparently
interfering with the effectiveness of such drugs, although the latter point
has not been completely investigated.</span><span style='font-size:11.0pt'> <br>
<o:p></o:p></span></p>
<p><b><span style='font-size:11.0pt;font-family:Arial'>BASELINE WORKUP</span></b><span
style='font-size:11.0pt'> <o:p></o:p></span></p>
<p><span style='font-size:11.0pt;font-family:Arial'>As with any cancer
treatment, it is important to establish certain baseline data before
commencing treatment, in order to monitor future therapeutic response. Such
baseline data will naturally vary depending on the type and extent of the
particular cancer being treated but will include patient's weight,
performance on the Karnovsky scale, full hematological profile, SMAC-16
biochemical profile, measurement of serum tumor marking proteins if present,
and clinical and radiological (including CAT-scan and NMR imaging if
appropriate) measurement of the extent of tumor load.</span><span
style='font-size:11.0pt'> <br>
<o:p></o:p></span></p>
<p><b><span style='font-size:11.0pt;font-family:Arial'>PRINCIPLE OF TREATMENT</span></b><span
style='font-size:11.0pt'> <o:p></o:p></span></p>
<p><span style='font-size:11.0pt;font-family:Arial'>Clinical experience
indicates that the best responses are obtained if one can maintain a
continuous high plasma ascorbate level. Ascorbate, however administered, is
rapidly excreted in the urine, so that administration should be continuous or
at very frequent intervals. Furthermore, exposure to high circulating levels
of ascorbate induces over-activity of certain hepatic enzymes concerned with
its degradation and metabolism. These enzymes persist for some time after
sudden cessation of high intakes, resulting in depletion of circulating
levels of ascorbate to well below normal unsupplemented values. This is known
as the rebound effect. It causes a sharp decrease in immunocompetence and
must be avoided in the cancer patient. Clinical experience has shown that the
best responses are observed when vitamin C is administered intravenously, so
insuring a high plasma level. However, because long-term continuous
intravenous administration is impractical, we recommend an initial
intravenous course of ten days duration, followed by continuous maintenance
oral regimen. If the patient's condition deteriorates, further intravenous
"booster" courses are recommended.</span><span style='font-size:
11.0pt'> <br>
<o:p></o:p></span></p>
<p><b><span style='font-size:11.0pt;font-family:Arial'>INTRAVENOUS VITAMIN C</span></b><span
style='font-size:11.0pt'> <o:p></o:p></span></p>
<p><span style='font-size:11.0pt;font-family:Arial'>Vitamin C intravenously
can be given by intermittent injection, but this is not recommended,
particularly if the intervals between injections extend to several days.
Because of the rebound effect, such administration would produce a sawtooth
plasma ascorbate profile with abnormally low levels in the troughs just prior
to the next injection. We recommend continuous administration via slow drip
infusion.</span><span style='font-size:11.0pt'> <o:p></o:p></span></p>
<p><span style='font-size:11.0pt;font-family:Arial'>It is recommended that
the patient be hospitalized for initial evaluation and commencing the
intravenous regimen. Intravenous vitamin C can cause troublesome chemical
phlebitis if injected directly into a superficial vein. Fo0r this reason it
is recommended that infusion be given via a C.V.P. (Central Venous Pressure,
or similar) line, with routine A-P portable chest X-ray taken after placement
to ensure that the catheter tip is correctly positioned in the Superior Vena
Cava. Alternately a "Hep-Lock" (or similar) cannula may be used in
a forearm vein with appropriate precautions against clotting.</span><span
style='font-size:11.0pt'> <o:p></o:p></span></p>
<p><b style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;
font-family:Arial'>(Additional information on intravenous vitamin C
administration is found <span style='mso-bidi-font-style:italic'>in<i> A
Physician's Handbook of Orthomolecular Medicine</i></span>, Roger J.
Williams, editor; at the website of Robert Cathcart, MD (</span></b><span
style='font-size:11.0pt;font-family:Arial'><a href="http://www.orthomed.com/">http://www.orthomed.com</a><b
style='mso-bidi-font-weight:normal'>); in Dr. Cathcart’s paper entitled
<i>Preparation of Sodium Ascorbate for IV and IM Use </i><span
style='mso-bidi-font-style:italic'>posted at </span></b><span
style='mso-bidi-font-style:italic'><a
href="http://www.doctoryourself.com/vitciv.html">http://www.doctoryourself.com/vitciv.html</a><b
style='mso-bidi-font-weight:normal'> </b></span><b style='mso-bidi-font-weight:
normal'>; and in <i>Clinical Guide to the Use of Vitamin C</i>, by Lendon
Smith, MD. The full text of Dr. Smith’s book is posted at</b> </span><span
style='font-size:9.0pt;font-family:Arial'><a
href="http://www.seanet.com/%7Ealexs/ascorbate/198x/smith-lh-clinical_guide_1988.htm">http://www.seanet.com/~alexs/ascorbate/198x/smith-lh-clinical_guide_1988.htm</a>
</span><b style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;
font-family:Arial'>. These sources discuss details including needle gauges
and buffers, among other topics.)</span></b><b style='mso-bidi-font-weight:
normal'><span style='font-size:11.0pt'> <o:p></o:p></span></b></p>
<p><span style='font-size:11.0pt;font-family:Arial'>The recommended
"carrier solution" is Ringer's Lactate Solution, readily available
in liter packs or flasks, and infused at the steady rate of 2 liters (two
packs) every 24 hours. Isotonic Dextrose should <b>never</b> be used as the
carrier solution. Vitamin C for parenteral use comes in sterile ampules of
sodium ascorbate preferably without preservative. Standard ampules contain
0.5g (500 milligrams), or as "multiuse" 50 ml ampules containing 25
grams. The ampules should be added to the infusion packs under full sterile
conditions in the Hospital Pharmacy or Infusion Fluids Department.</span><span
style='font-size:11.0pt'> <o:p></o:p></span></p>
<p><span style='font-size:11.0pt;font-family:Arial'>In patients not
previously exposed to high levels of ascorbate, a gradual "wind-up"
dose regimen is recommended, along the following lines:</span><span
style='font-size:11.0pt'> <o:p></o:p></span></p>
<p><span style='font-size:11.0pt;font-family:Arial'>Day One to the first
flask add 0.5g sodium ascorbate</span><span style='font-size:11.0pt'> <o:p></o:p></span></p>
<p><span style='font-size:11.0pt;font-family:Arial'>to the second 1.0g sodium
ascorbate</span><span style='font-size:11.0pt'> <o:p></o:p></span></p>
<p><span style='font-size:11.0pt;font-family:Arial'>to the third 1.5g sodium
ascorbate</span><span style='font-size:11.0pt'> <o:p></o:p></span></p>
<p><span style='font-size:11.0pt;font-family:Arial'>to the fourth 2.0g sodium
ascorbate</span><span style='font-size:11.0pt'> <o:p></o:p></span></p>
<p><span style='font-size:11.0pt;font-family:Arial'>Day Two to the fifth
flask add 2.5g sodium ascorbate</span><span style='font-size:11.0pt'> <o:p></o:p></span></p>
<p><span style='font-size:11.0pt;font-family:Arial'>(continuing at that level
infuses 10g sodium ascorbate per day)</span><span style='font-size:11.0pt'> <o:p></o:p></span></p>
<p><span style='font-size:11.0pt;font-family:Arial'>Much higher doses can be
and have been infused with perfect safety, the limiting factor being sodium
overload with water retention, and not the ascorbate ion itself. The wind-up
dosage schedule is not necessary in patients receiving "booster"
repeat courses.</span><span style='font-size:11.0pt'> <o:p></o:p></span></p>
<p><span style='font-size:11.0pt;font-family:Arial'>PRECAUTIONS: Standard
continuous infusion procedure must be followed. It is not necessary to
monitor serum electrolyte levels except in patients with gross cardiac or
renal impairment.</span><span style='font-size:11.0pt'> <o:p></o:p></span></p>
<p><span style='font-size:11.0pt;font-family:Arial'>SIDE-EFFECTS There are
two recognized side-effects, one very common and relatively harmless, the
other very rare and highly dangerous. The common side-effect is transient
fluid retention due to sodium overload resulting in some ankle edema in the
ambulant and sacral pad edema in those confined to bed. Inpatients with
cardiac impairment dangerous pulmonary edema may develop and require
intravenous frusemide for its control.</span><span style='font-size:11.0pt'> <o:p></o:p></span></p>
<p><span style='font-size:11.0pt;font-family:Arial'>The rare side-effect,
seen only in patients with highly anaplastic very rapidly growing tumors and
a heavy tumor load, is the sudden precipitation of widespread tumor necrosis.
Clinically this is heralded by sudden pain in all tumor deposits, rapid
swelling of known tumors, tumor hemorrhage, both internal and external,
hyperpyrexia, severe hypotension,</span><span style='font-size:11.0pt'> <o:p></o:p></span></p>
<p><span style='font-size:11.0pt;font-family:Arial'>tachycardia and azotemia.
This very rare complication can be fatal and must be vigorously treated. If
suspected, the ascorbate infusion should be immediately stopped, and the
patient treated as for septicemic shock. The patient may require transfer to
the Intensive Care Unit for close monitoring and support by oxygen, plasma or
blood, and intravenous steroids. If resuscitation is successful, it will be
found that any residual tumor has shrunk considerably or even disappeared.
Although highly dangerous, this reaction might also be termed the best
possible response to ascorbate treatment of wide-spread cancer.</span><span
style='font-size:11.0pt'> <br>
<o:p></o:p></span></p>
<p><b><span style='font-size:11.0pt;font-family:Arial'>ORAL VITAMIN C</span></b><span
style='font-size:11.0pt'> <o:p></o:p></span></p>
<p><span style='font-size:11.0pt;font-family:Arial'>On the day planned to
terminate intravenous ascorbate, the patient should be commenced on oral
ascorbate at the same daily intake. The medication should be taken every six
hours (four times a day), and once commenced should never be abruptly
discontinued because of the rebound effect. The dose varies between
individuals in the 10 to 30g a day range. The aim should be to maintain
plasma ascorbate levels of at least 3mg/dl for effective therapy. Leukocyte
ascorbate concentration, a technically more difficult estimation to perform,
is of much less value in predicting response to treatment.</span><span
style='font-size:11.0pt'> <br>
<o:p></o:p></span></p>
<p><b><span style='font-size:11.0pt;font-family:Arial'>RESPONSE TO ASCORBATE
TREATMENT</span></b><span style='font-size:11.0pt'> <o:p></o:p></span></p>
<p><span style='font-size:11.0pt;font-family:Arial'>As with any other form of
cancer treatment, therapeutic response will vary between individual patients,
with paradoxically the best responses seen with individuals with far advanced
disease. Therapeutic responses may be listed as follows:</span><span
style='font-size:11.0pt'> <o:p></o:p></span></p>
<p><span style='font-size:11.0pt;font-family:Arial'>1. No response detectable
(a very few)</span><span style='font-size:11.0pt'> <o:p></o:p></span></p>
<p><span style='font-size:11.0pt;font-family:Arial'>2. Some retardation of
progressive tumor growth (very many)</span><span style='font-size:11.0pt'> <o:p></o:p></span></p>
<p><span style='font-size:11.0pt;font-family:Arial'>3. Stasis or standstill
effect (considerable number)</span><span style='font-size:11.0pt'> <o:p></o:p></span></p>
<p><span style='font-size:11.0pt;font-family:Arial'>4. Tumor regression (a
few)</span><span style='font-size:11.0pt'> <o:p></o:p></span></p>
<p><span style='font-size:11.0pt;font-family:Arial'>5. Tumor necrosis (very
rare)</span><span style='font-size:11.0pt'> <o:p></o:p></span></p>
<p><span style='font-size:11.0pt;font-family:Arial'>A typical response to
ascorbate can be described as follows:</span><span style='font-size:11.0pt'> <o:p></o:p></span></p>
<p><span style='font-size:11.0pt;font-family:Arial'>An improvement in
well-being, vigor and Karnovsky performance status will be apparent in 5 to 7
days. Originally thought to be a purely subjective response, it is now
realized to be objective and due to restoration of endogenous carnitine
biosynthesis, carnitine being responsible for transporting triglycerides
across the mitochondrial membrane where they are burned for muscle energy.</span><span
style='font-size:11.0pt'> <o:p></o:p></span></p>
<p><span style='font-size:11.0pt;font-family:Arial'>If painful skeletal
metastases are present, relief of bone pain will occur in about 5 to 7 days, <b>enabling
opiates to be withdrawn without withdrawal symptoms</b>. Skeletal or
widespread visceral metastases are associated with increased urinary
hydroxyproline (UHP) excretion reflecting collagen breakdown. <b>Within 5
days of commencing ascorbate therapy, a sharp and sustained fall in UHP
excretion will be noted</b>.</span><span style='font-size:11.0pt'> <o:p></o:p></span></p>
<p><span style='font-size:11.0pt;font-family:Arial'>Response to treatment
will also be reflected in a drop in the sedimentation rate and fall in the
titer of any serum tumor protein markers (CEA etc.) if present.</span><span
style='font-size:11.0pt'> <o:p></o:p></span></p>
<p><span style='font-size:11.0pt;font-family:Arial'>Radiological signs of
good response include the slow conversion of osteolytic skeletal metastases
to dense osteosclerotic lesions over a period of months. In favorable cases,
resorption of malignant pleural effusions and reduction in size of pulmonary
metastases have been observed.</span><span style='font-size:11.0pt'> <br>
<o:p></o:p></span></p>
<p><b><span style='font-size:11.0pt;font-family:Arial'>CONTINUATION OF
TREATMENT</span></b><span style='font-size:11.0pt'> <o:p></o:p></span></p>
<p><span style='font-size:11.0pt;font-family:Arial'>Oral ascorbate should be
continued indefinitely and the patient carefully monitored at least every
month. The usual course of events is that the patient instead of slowly
declining will enter a plateau of comparative well-being that may continue
for many months or even years, and then enter an abrupt downhill phase with
explosive metastases. At the first suspicion of this change, a
"booster" course of intravenous ascorbate is recommended, even
though individual responses can never be predicted. Over a period of three
years, one patient with widespread leiomyosarcoma had six such booster courses
with clear benefit from each one except the last. Many other patients have
shown no benefit from even the first booster course, but it is always worth
trying.</span><span style='font-size:11.0pt'> <br>
<o:p></o:p></span></p>
<p><b><span style='font-size:11.0pt;font-family:Arial'>INTRACAVITARY
ASCORBATE</span></b><span style='font-size:11.0pt'> <o:p></o:p></span></p>
<p><span style='font-size:11.0pt;font-family:Arial'>Isotonic solutions of
sodium ascorbate (2.97g sodium ascorbate in 100 ml sterile distilled water
for injection) have been instilled in the peritoneal and pleural cavities
after paracentesis or thoraocentesis for malignant effusions. Benefit
appeared to ensue in the sense of reduction in the rate of effusion
accumulation, although without controls this impression is difficult to
prove. At least clinical experience has shown that the procedure is quite
painless and perfectly safe.</span><span style='font-size:11.0pt'> <br>
<o:p></o:p></span></p>
<p><b><span style='font-size:11.0pt;font-family:Arial'>KIDNEY
"DAMAGE"</span></b><span style='font-size:11.0pt'> <o:p></o:p></span></p>
<p><span style='font-size:11.0pt;font-family:Arial'>There is a widespread
belief in the medical profession that large intakes of vitamin C might
somehow cause kidney damage. This apparently stems from a (1954) study that
showed that in some individuals (5 percent of those tested) intakes of
vitamin C above 4 grams per day resulted in a measurable increase in urinary
oxalate levels with a theoretical risk of oxalate stone formation. Doubts
have been expressed about the specificity of the assay method used, and
studies on healthy individuals ingesting large amounts of vitamin C for years
have shown plasma and urinary oxalate levels well within normal range. No
instance of this complication has been encountered in over 100 cancer
patients under the author's care, or in many other patients ingesting
multigram amounts of ascorbate for many years. The risk of stone formation,
if it exists at all, must be extremely remote, and more than offset by the
potential benefit to the cancer patient. (Additional information refuting
alleged vitamin-caused kidney stones is found in <i>The Vitamin C Connection</i>,
by Emanuel Cheraskin, MD, et al, and <i>How to Live Longer and Feel Better</i>,
by Linus Pauling, PhD.)</span><span style='font-size:11.0pt'> <o:p></o:p></span></p>
<p><span style='font-family:Arial'>(Note: Within this paper, Dr. Cameron
cited 38 references, and recommended 11 additional sources. The complete
bibliography is posted at </span><span style='font-size:11.0pt'><a
href="http://www.doctoryourself.com/biblio_cameron.html"><span
style='font-family:Arial;mso-bidi-font-weight:bold'>http://www.doctoryourself.com/biblio_cameron.html</span><span
style='font-family:Arial'>)</span></a></span><span style='font-size:11.0pt;
font-family:Arial'> <o:p></o:p></span></p>
<p><b style='mso-bidi-font-weight:normal'><span style='font-size:10.0pt;
font-family:Arial'>Andrew Saul is the <span class=grame>author of the books <i>FIRE</i></span><i>
YOUR DOCTOR!</i> How <i>to be Independently Healthy </i>(reader reviews at<i>
</i><a href="http://www.doctoryourself.com/review.html">http://www.doctoryourself.com/review.html</a>
) and <i>DOCTOR YOURSELF: Natural Healing that Works.</i> (reviewed at <a
href="http://www.doctoryourself.com/saulbooks.html">http://www.doctoryourself.com/saulbooks.html</a>
) </span><o:p></o:p></b></p>
<p><b style='mso-bidi-font-weight:normal'><span style='font-size:10.0pt;
font-family:Arial'>For ordering information, <a
href="http://www.doctoryourself.com/order.html">Click here</a></span> .<o:p></o:p></b></p>
<p><span style='font-family:Arial'><o:p> </o:p></span></p>
<p><span style='font-family:Arial'><o:p> </o:p></span></p>
</td>
</tr>
<tr style='mso-yfti-irow:1'>
<td style='padding:0in 0in 0in 0in'>
<p class=MsoNormal align=center style='text-align:center'><a
href="contact.html"><span style='text-decoration:none;text-underline:none'><img
border=0 width=55 height=60 id="_x0000_i1029"
src="images/e-mail.gif"></span></a><br>
<a href="contact.html">Andrew W. Saul</a></p>
</td>
<td style='padding:0in 0in 0in 0in'>
<p class=MsoNormal><o:p> </o:p></p>
</td>
<td style='padding:0in 0in 0in 0in'>
<div class=MsoNormal align=center style='text-align:center'>
<hr size=2 width="100%" align=center>
</div>
<p class=MsoNormal><span style='font-size:7.5pt'>AN IMPORTANT NOTE: This
page is not in any way offered as prescription, diagnosis nor treatment for
any disease, illness, infirmity or physical condition. Any form of
self-treatment or alternative health program necessarily must involve an
individual's acceptance of some risk, and no one should assume
otherwise. Persons needing medical care should obtain it from a
physician. Consult your doctor before making any health decision. </span>
</p>
<p><span style='font-size:7.5pt'>Neither the author nor the webmaster has
authorized the use of their names or the use of any material contained within
in connection with the sale, promotion or advertising of any product or
apparatus. Single-copy reproduction for individual, non-commercial use is
permitted providing no alterations of content are made, and credit is given.</span>
</p>
<div class=MsoNormal align=center style='text-align:center'>
<hr size=2 width="100%" align=center>
</div>
<p class=MsoNormal align=center style='text-align:center'></p>
</td>
</tr>
<tr style='mso-yfti-irow:2;mso-yfti-lastrow:yes'>
<td style='padding:0in 0in 0in 0in'>
<p class=MsoNormal><o:p> </o:p></p>
</td>
<td style='padding:0in 0in 0in 0in'>
<p class=MsoNormal><o:p> </o:p></p>
</td>
<td style='padding:0in 0in 0in 0in'>
<p class=MsoNormal align=center style='text-align:center'><span
style='font-size:10.0pt;font-family:Arial'>| <a
href="index.html">Home</a> | <a
href="order.html">Order my Books</a> | <a
href="aboutme.html">About the Author</a> | <a
href="contact.html">Contact Us</a> | <a
href="webmaster.html">Webmaster</a> |</span></p>
</td>
</tr>
</table>
<p class=MsoNormal><o:p> </o:p></p>
</div>
<!-- ADD TBlock1 ===================== -->
<a name="translator_block"></a>
<br>
<div id="MicrosoftTranslatorWidget" style="width: 200px; min-height: 0px; border-color: #3A5770; background-color: #78ADD0;">
<noscript>
<a href="http://www.microsofttranslator.com/bv.aspx?a=http%3a%2f%2fwww.doctoryourself.com%2f">
Translate this page
</a>
<br />
Powered by
<a href="http://www.microsofttranslator.com">
Microsoft® Translator
</a>
</noscript>
</div>
<script type="text/javascript">
/* <![CDATA[ */
setTimeout(function()
{ var s = document.createElement("script");
s.type = "text/javascript"; s.charset = "UTF-8";
s.src = "http://www.microsofttranslator.com/Ajax/V2/Widget.aspx?mode=manual&from=en&layout=ts";
var p = document.getElementsByTagName('head')[0] || document.documentElement;
p.insertBefore(s, p.firstChild); }, 0);
/* ]]> */
</script>
<br>
<!-- ===================== -->
<!-- Use this block only in a REPLACE statement : it contains extra characters ! -->
<!-- ===================== -->
<!-- Note: -must- "escape" the "</body>" in the s.src line on find-and-replace ===================== -->
<!-- END ADD TBlock1 ===================== -->
</body>
</html>
|
